(Supported by the Louisiana Cancer Research Consortium)
(Sponsored CME series)
Time & Location:
1st & 3rd Thursday at Noon
Louisiana Cancer Research Center
1700 Tulane Ave., 1st Floor Conference Room
(unless otherwise noted)
Statement of Need: The purpose of the Stanley S. Scott Cancer Center (SSSCC) Invited Speaker Series is to fulfill an educational need in the local community by providing the latest research and findings in the field of oncology. In this capacity the series serves to build upon the competencies of those in attendance as a resource for information on research and treatment protocols. Communication among physicians and researchers to share their experiences in clinical and laboratory settings is encouraged to foster an atmosphere of collaboration. Presentations and discussion of current topics helps to keep audience members informed on the latest research and developments in cancer diagnosis and treatment.
Target Audience: The target audience for this activity includes oncologists, hematologists, nurses, techs, medical students, and health care providers with an interest in cancer treatment and research.
Objectives: After participating in this educational activity, the attendee should be better able to:
Accreditation/Designation of Credit: LSU School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
LSU School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
LSU School of Medicine presents this activity for educational purposes only and does not endorse any product, content of presentation or exhibit. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected because of their recognized expertise.
Facilitated by: The LSU Health Sciences Center – Institute of Professional Education
Faculty Disclosure: It is the policy of Continuing Education at LSU School of Medicine to plan and implement all of its educational activities in accordance with the ACCME’s Essential Areas and Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME’s 2004 Standards for Commercial Support, everyone who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all relevant financial relationships with any commercial interests within the past 12 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. Individuals with potential for influence or control of CME content include planners and planning committee members, authors, teachers, educational activity directors, educational partners, and others who participate, e.g. facilitators and moderators. This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational drugs or devices must also be made known to the audience.
|March 1||Jennifer Yu, M.D., Ph.D.
Department of Molecular Medicine
Cleveland Clinic Lerner College of Medicine
|“Glioma Stem Cells in Their Niches”|
|March 15||Qiang Shen, M.D., Ph.D.
Department of Clinical Cancer Prevention
University of Texas M.D. Anderson Cancer Center
|“Identifying Molecular Targets and Developing Novel Therapy for Cancer Prevention and Treatment”|
|March 29||Ratna Vadlamudi, Ph.D.
Department of Cell Systems and Anatomy
University of Texas Health Science Center at San Antonio
San Antonio, TX
|“Estrogen Receptor Coregulator Binding Modulators (ERXs) as Novel Therapeutics for Breast Cancer”|
|April 5||Lopa Mishra, M.D.
Department of Surgery
George Washington University
|“Cancer Stem Cells, Hepatocellular Cancer and TGF-beta Signaling”|
|May 3||Bing-Hua Jiang, Ph.D.
Department of Pathology
University of Iowa Carver College of Medicine
Iowa City, IA
|“MicroRNAs and Oxidative Stress in Carcinogenesis, Cancer Development, and Therapeutic Resistance”|
|May 17||Vivek Rangnekar, Ph.D.
Professor and Alfred Cohen Chair in Oncology Research
University of Kentucky College of Medicine
|“Empowering Normal Cells Against Cancer”|
|June 21||Judy N. Quong, Ph.D.
American Association for Cancer Research
|August 16||Shrikant Anant, Ph.D.
Department of Surgery
University of Kansas Medical Center
Kansas City, KS
|September 20||Ruiwen Zhang, M.D., Ph.D., DABT, FAAAS
Professor of Pharmacology and Toxicology
University of Houston
|October 18||William T. Beck, Ph.D.
Professor of Pharmacology and Molecular Genetics
University of Illinois at Chicago
|November 15||Yong Wan, Ph.D.
Department of Obstetrics and Gynecology
Department of Pharmacology
Northwestern University Feinberg School of Medicine
|January 19||J. Silvio Gutkind, Ph.D.
Professor, Department of Pharmacology
UC San Diego Moores Cancer Center
La Jolla, CA
|“Targeting the PI3K/mTOR Signaling Circuitry for Precision Cancer Prevention and Treatment”|
|February 2||Kathleen Schmeler, M.D.
Department of Gynecologic Oncology
University of Texas MD Anderson Cancer Center
Using Project ECHO to Expand Cancer Prevention and Care to the Community”
||Michael Shurin, M.D., Ph.D.
Associate Professor of Pathology
University of Pittsburgh Medical Center
|“Neuroglia as a New Player in the Tumor Immunoenvironment”|
|March 16||Murray Korc, M.D.
Professor of Medicine, Biochemistry, and Molecular Biology
Indiana University School of Medicine
|“Targeted Precision Medicine in
Pancreatic Ductal Adenocarcinoma”
||Eduardo Davila, Ph.D.
Associate Professor of Microbiology and Immunology
University of Maryland School of Medicine
|“Intensifying T Cell Responses to
Weakly Immunogenic or
Lowly Expressed Tumor Antigens”
|May 4||Xiaoqi Liu, Ph.D.
Professor of Biochemistry
West Lafayette, IN
|“Polo-like Kinase 1: From Cell
Biology To Cancer Therapeutics”
|May 18||Sudhir Srivastava, Ph.D., MPH
Chief, Early Detection Research Network (EDRN)
|“The Nuances of Cancer Biomarker Discovery and Validation: What Do You Need To Know?”|
|June 1||Hui-Wen Lo, Ph.D.
Department of Cancer Biology
Wake Forest University
|“tGLI1 in Breast Cancer Metastasis and Glioblastoma Progression: Angiogenesis, Stem Cells and Tumor Microenvironment”|
|September 21||Lin Zhang, Ph.D.
Professor, Department of Pharmacology and Chemical Biology
University of Pittsburgh School of Medicine
|“Cell Death Regulation in the Precision Treatment of Colorectal Cancer”|
|October 18||Bolin Liu, M.D.
Department of Pathology
University of Colorado
|“ErbB3-miRNA Signaling Axis in ErbB2-Positive Breast Cancer Progression”|
|October 19||Andrew Thorburn, D.Phil
Professor and Chairman
Department of Pharmacology
University of Colorado School of Medicine
|“Autophagy, Cell Death and Cancer Therapy”|
|November 2||Ernest Hawk, M.D., M.P.H.
Boone Pickens Distinguished Chair for Early Prevention of Cancer
Department of Cancer Prevention
MD Anderson Cancer Center
|“Integrating Cancer Prevention Through Personal and Public Actions: MD Anderson’s Approach”|
||Gary A. Piazza, Ph.D.
Professor of Oncologic Sciences and Pharmacology
University of South Alabama
|“A Chemical Biology Approach Using a Custom Indene Library to Identify Novel Cancer Targets and Drug Development Candidates”|
Joshua Lovell, B.A.
Academic Coordinator for the Invited Speaker Series:
Yaguang Xi, M.D., Ph.D., MBA